Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
GLUE reported a proposed sale of 2,175 shares of Common Stock via a Form 144. The filing states the shares arise from an exercise of stock options with an indicated date of 05/27/2026. The filing also lists 2,176 shares sold during the prior three months (date 05/22/2026) and an amount of $42,042.75 shown on the form.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sell transaction in company stock. On May 22, 2026, she exercised stock options to acquire 2,176 shares of common stock at $3.98 per share and, on the same date, completed an open-market sale of 2,176 shares at $19.00 per share. After these transactions, she directly held 62,371 shares of Monte Rosa Therapeutics common stock. The filing notes that the transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating they were scheduled in advance.
Monte Rosa Therapeutics director Anthony M. Manning reported an option exercise-and-sale transaction in the company’s stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then sold 10,000 shares in an open-market transaction at $18.01 per share on the same date.
Following these transactions, Manning reported holding no shares of common stock directly, while retaining stock options covering 12,100 shares at a $4.16 exercise price that are fully vested and exercisable and expire on June 12, 2034.
Monte Rosa Therapeutics, Inc. Schedule 13G/A amendment reports that the Reporting Persons collectively hold 4,622,151 shares of Common Stock, representing 5.5% of the class based on 84,479,418 shares outstanding as of May 1, 2026. The holdings consist of two fund vehicles each holding 2,311,076 and 2,311,075 shares, and the reporting individual, Chen Yu, is disclosed as sharing voting and dispositive power through related general partner entities.
The filing clarifies ownership and voting/dispositive arrangements under Rule 13d-1(k)(1) and includes the reporting persons' address and organizational details. The statement notes potential shared voting and investment power among the named entities and that the Reporting Persons disclaim group status.
Monte Rosa Therapeutics, Inc. ownership amendment: Baker Bros. Advisors, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker filed Amendment No. 2 to report beneficial ownership positions in the issuer. The filing states 8,876,346 shares (9.99% of Common Stock) attributed to each of the named Reporting Persons and discloses 4,530,610 pre-funded warrants exercisable subject to a Maximum Percentage exercise limitation. The percentage calculations use 84,321,705 shares outstanding as of March 31, 2026.
Biotechnology Value Fund and affiliated reporting persons filed an amended Schedule 13G/A disclosing shared beneficial ownership in Monte Rosa Therapeutics common stock. As of March 31, 2026, BVF directly held 2,716,569 shares (approximately 3.4%) and BVF II held 1,986,984 shares (approximately 2.5%), with aggregate attributable positions reported up to 5,085,886 shares (approximately 6.3%) under certain entities. The filing states 80,015,667 Shares outstanding as of March 2, 2026 was used to compute percentages and describes 625,000 shares underlying pre-funded warrants exercisable at $0.0001 per share, subject to a 9.99% exercise blocker.
Monte Rosa Therapeutics reported a net loss of $44.5 million for the three months ended March 31, 2026, compared with net income of $46.9 million a year earlier. Collaboration revenue fell to $4.2 million from $84.9 million as prior-period payments were not repeated.
Research and development expense rose to $44.1 million, reflecting broader pipeline activity, while general and administrative costs increased modestly to $10.2 million. The company ended the quarter with $666.2 million in cash, cash equivalents and marketable securities and $671.2 million including restricted cash, and expects this to fund operations into 2029.
Monte Rosa Therapeutics reported a first quarter 2026 net loss of $44.5 million, compared with net income of $46.9 million a year earlier, as collaboration revenue normalized after large 2025 milestone payments. Q1 2026 collaboration revenue fell to $4.2 million from $84.9 million.
Research and development expenses rose to $44.1 million and general and administrative costs to $10.2 million, reflecting expansion of clinical and discovery programs. Cash, cash equivalents, restricted cash, and marketable securities reached $671.2 million, and the company expects this balance to fund operations into 2029 while it advances multiple Phase 2 studies and new IND filings.